CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.126
https://www.valueinhealthjournal.com/article/S1098-3015(23)03256-4/fulltext
Title :
CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03256-4&doi=10.1016/j.jval.2023.09.126
First page :
Section Title :
Open access? :
No
Section Order :
10718